Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: July 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020297

« Back to Dashboard

NDA 020297 describes COREG, which is a drug marketed by Smithkline Beecham and is included in two NDAs. It is available from three suppliers. There are two patents protecting this drug and three Paragraph IV challenges. Additional details are available on the COREG profile page.

The generic ingredient in COREG is carvedilol phosphate. There are thirty-six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the carvedilol phosphate profile page.

Summary for 020297

Tradename:	COREG
Applicant:	Smithkline Beecham
Ingredient:	carvedilol
Patents:	0
Therapeutic Class:	Cardiovascular Agents
Formulation / Manufacturing:	see details

Pharmacology for NDA: 020297

Mechanism of Action	Adrenergic alpha-Antagonists Adrenergic beta1-Antagonists Adrenergic beta2-Antagonists

Suppliers and Packaging for NDA: 020297

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
COREG	carvedilol	TABLET;ORAL	020297	NDA	GlaxoSmithKline LLC	0007-4139	N	0007-4139-20
COREG	carvedilol	TABLET;ORAL	020297	NDA	GlaxoSmithKline LLC	0007-4140	N	0007-4140-20

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	25MG
Approval Date:	Sep 14, 1995	TE:	AB	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	12.5MG
Approval Date:	Sep 14, 1995	TE:	AB	RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	6.25MG
Approval Date:	Sep 14, 1995	TE:	AB	RLD:	Yes

Expired US Patents for NDA 020297

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-002	Sep 14, 1995	➤ Sign Up	➤ Sign Up
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-003	Sep 14, 1995	➤ Sign Up	➤ Sign Up
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-003	Sep 14, 1995	➤ Sign Up	➤ Sign Up
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-004	May 29, 1997	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.